Amedica/US Spine, a Salt Lake City-based spine and reconstructive implant and instrument manufacturer, recently completed a distribution and licensing agreement with the Memphis-based BioDlogics to distribute the company's biologic products, according to an Amedica/US Spine news release.
Under the agreement, Amedica/US Spine will distribute BioDlogics' stem cell products for spinal fusion, adhesion barrier and nerve protection. Ben Shappley, president and CEO of Amedica/US Spine, says the agreement will increase the company's presence in the biologic market and complements the line of MC2 Silicon Nitride spine spacers it already offers.
The BioDfence and BioDfactor products are packaged at an FDA-registered tissue bank.
Read more about the agreement between Amedica/US Spine and BioDlogics.
Read more about Amedica/US Spine:
- Amedica Acquires US Spine
- Amedica Patents Motion-Preserving Spine Implant
- Amedica Receives Patent for Knee Prosthesis
Under the agreement, Amedica/US Spine will distribute BioDlogics' stem cell products for spinal fusion, adhesion barrier and nerve protection. Ben Shappley, president and CEO of Amedica/US Spine, says the agreement will increase the company's presence in the biologic market and complements the line of MC2 Silicon Nitride spine spacers it already offers.
The BioDfence and BioDfactor products are packaged at an FDA-registered tissue bank.
Read more about the agreement between Amedica/US Spine and BioDlogics.
Read more about Amedica/US Spine:
- Amedica Acquires US Spine
- Amedica Patents Motion-Preserving Spine Implant
- Amedica Receives Patent for Knee Prosthesis